NASDAQ:EKSO Ekso Bionics Q1 2024 Earnings Report $10.88 +0.07 (+0.65%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$10.84 -0.04 (-0.32%) As of 04/17/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Provident Bancorp EPS ResultsActual EPS-$0.20Consensus EPS -$0.16Beat/MissMissed by -$0.04One Year Ago EPS-$0.33Provident Bancorp Revenue ResultsActual Revenue$3.76 millionExpected Revenue$4.99 millionBeat/MissMissed by -$1.23 millionYoY Revenue GrowthN/AProvident Bancorp Announcement DetailsQuarterQ1 2024Date4/29/2024TimeAfter Market ClosesConference Call DateMonday, April 29, 2024Conference Call Time4:30PM ETUpcoming EarningsProvident Bancorp's Q1 2025 earnings is scheduled for Thursday, April 24, 2025Conference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Provident Bancorp Q1 2024 Earnings Call TranscriptProvided by QuartrApril 29, 2024 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:00Greetings and welcome to the Ekso Bionics First Quarter 20 24 Financial Results Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce Matt Steinberg with Fin Partners. Operator00:00:26Thank you. You may begin. Speaker 100:00:28Thank you, operator, and thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer Jerome Wong, Chief Financial Officer and Jason Jones, Chief Operating Officer. Earlier today, Ekso Bionics released financial results for the quarter ended March 31, 2024. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Speaker 100:01:11Any statements made during this call that are not statements of historical facts should be deemed to be forward looking statements. All forward looking statements, including statements regarding our business strategy, future financial or operational expectations or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with Ekso's businesses, please see its filings with the Securities and Exchange Commission. Speaker 100:02:00Ekso disclaims any obligation, except as required by law, to update or revise any financial or operational projections, its regulatory outlook or other forward looking statements, whether because of new information, future events or otherwise. Any forward looking statements made on this call speak only as of the date of this call. I will now turn the call over to Ekso Bionics' Chief Executive Officer, Scott Davis. Speaker 200:02:28Thank you, Matt. We closed out the Q1 and started the Q2 of 2024 with positive momentum as we were pleased to receive final payment determination for Medicare reimbursement of our Ekso Indigo Personal. Additionally, our results for the quarter reflect continued improvements from both our scalable commercial strategy and operations. I'll touch on both of these developments shortly, but first I'll share an overview of our Q1 performance. We generated revenue of $3,800,000 and sold 29 EksoHealth devices in the Q1 of 2024. Speaker 200:03:04Sales of the EksoHealth devices for the quarter were slightly more affected by typical seasonality due primarily to fluctuations in larger integrated delivery network or IDM procurement cycles. We remain focused on executing upon our commercial strategy and growing our IDN network. We continue to deploy resources to develop new IDN relationships that will help us secure larger and more multi unit capital deals across our North American network. In doing so, we aim to convey the clear clinical and economic benefits of our EksoNR and our Ekso Indigo Therapy devices with the right decision makers. Our pipeline of potential deals remains solid with approximately $1,000,000 of backlog generated in Q1 to be recognized over the course of 2024 and we remain confident that our commercial team will succeed in driving larger unit order growth. Speaker 200:04:01Now turning to an Ekso Indigo personal update. As previously announced, CMS approved use of healthcare common procedure coding system K1007 to bill Medicare for the Ekso Indigo Personal. On April 11, CMS established a reimbursement level of $91,031 for Medicare reimbursement under this code, the Ekso Indigo Personal, effective retroactively beginning April 1. This pricing decision from CMS is an important next step in our commercial strategy to build demand within clinical, home and community use settings. We believe there are thousands of Medicare and Medicaid covered individuals with a spinal cord injury that could potentially benefit from our differentiated personal exoskeleton device, enabling them to achieve better health outcomes along with new levels of independence. Speaker 200:04:56We're thrilled that our differentiated exoskeleton devices are now accessible to a larger patient population and we look forward to providing future updates on our continued work with the SCI community, CMS, along with other public and private health insurance programs that generally follow CMS reimbursement practices. With reimbursement pricing secured, we anticipate growing the personal health business. We believe this growth will ramp up quarter over quarter as our commercial and clinical teams engage with skilled therapists and clinicians across our expansive customer base consisting of more than 260 clinical and rehabilitation centers domestically. We're leveraging our robust network to expand our reach to a potentially higher volume of individuals living with a spinal cord injury who we benefit from our Ekso Indigo Personal through establishing additional certified training centers across the U. S. Speaker 200:05:49Turning to our international performance, we're pleased that we continue to gain momentum across the EMEA and APAC regions. Results were particularly strong in EMEA as the French public health system has embraced the use of robotics in their neuro rehabilitation programs. Looking ahead, we are working to continue to build on the strength of our vast international distribution network, which serves as our focal point of achieving operating leverage and scalable worldwide growth. Now I'd like to turn to an update on our Industrial segment, EksoWorks. In the Q1 of 2024, sales within this segment increased nearly 60% from the same period a year ago, although against a modest level. Speaker 200:06:31Notably, we delivered devices to an OEM in the construction vertical along with continued shipments to potentially large volume customers in aerospace and energy segments. With improved cost structures driven by our new contract manufacturer, we remain focused on scaling our commercial growth through targeted customers in large industrial settings. Overall, our performance in the Q1 of 2024 demonstrated continued progress across both of our segments. Now with CMS establishing reimbursement pricing for the Ekso Indigo Personal, we believe we are poised to take the next step in our evolution. At this time, I'd like to turn the call over to our Chief Financial Officer, Jerome Wong to review our Q1 financial results. Speaker 300:07:15Thank you, Scott. We generated Q1 2024 revenue of $3,800,000 compared to $4,100,000 for the Q1 of 20 23. Gross profit for the 1st quarters of 20242023 was CAD2 1,000,000 in both periods, representing a gross margin of approximately 52% in the Q1 of 2024 compared to a gross margin of 49% for the Q1 of 2023. The overall increase in gross margin was primarily due to lower EksoHealth device and service costs. Operating expenses for the Q1 of 2024 were $5,200,000 compared to $6,400,000 for the Q1 of 2023. Speaker 300:08:00The 19% decrease was primarily due to a decrease in general and administrative expenses stemming from lower legal expenses, headcount and the absence of costs associated with the acquisition and integration of HMC in the comparable quarter. Net loss applicable to common stockholders for the Q1 was $3,400,000 or $0.20 per basic and diluted share, compared to a net loss of $4,400,000 or $0.33 per basic and diluted share for the same period in 2023. Cash and restricted cash as of March 31, 2024 was $8,800,000 compared to $8,600,000 as of December 31, 2023. Please see our Form 10 Q filed earlier today for further details regarding the quarter. Operator, you may now open the line for questions. Operator00:08:55Thank you. Ladies and gentlemen, at this time, we will be conducting a question and answer Our first question comes from the line of Sean Lee with H. C. Wainwright. Please proceed with your question. Speaker 400:09:31Good afternoon, guys. This is Sean from H. C. Wainwright. How are you? Speaker 200:09:37I'm well, Sean. Thank you. Speaker 400:09:40My first question is on the recent approval by Medicare on the reimbursement. So I was wondering, it's been about 2 weeks since, have you seen any increase in lead generation or interest in this device as a result of the Medicare approval? Speaker 200:09:59Yes. So thank you, Shlomo, for your question. In general, we are seeing strong demand from individuals with spinal cord injuries who are interested in the technology. So we saw a definite uptick from the announcement of final payment termination. So yes, is the short answer to that question. Speaker 200:10:28And we are working to support our DMEs to be able to get those Medicare claims submitted. Speaker 400:10:40That's great to hear. On the elaborating on these claims, so I was wondering, does having a standardized reimbursement number streamline your sales cycle such that it makes it easier for you to market and sell these devices? Speaker 200:11:02Again, the short answer to that is yes, absolutely. Previously, with the code approved, but on a case by case basis, the level of documentation that's required for that is fairly significant. And it's a rather unusual process to physicians who might be submitting a prescription for this or to DMEs who need to process it. With CMS establishing a payment determination, this claim now has an actual cash value behind it. So as those claims are being submitted, there is a recognized value that has been definitively provided by CMS. Speaker 200:11:56So it is a more of a standardized process at this point in time. Speaker 400:12:02That's great to hear. Thanks for that. My final question then is on the international sector. You mentioned that you're gaining momentum, especially in India. So I was wondering, is that something that we could see going forward for the remainder of the year as well? Speaker 400:12:17Or is it more of a one time bolus in the Q1? Speaker 200:12:22Okay. In the EMEA region, yes. So we are seeing good growth there and part of that growth is attributed to the strong distribution network that we've built throughout both EMEA and APAC regions. We've been hard at work in developing our distributor network over many years now and we are definitely seeing scale through that use of that channel. Additionally, there's been a significant project within the French healthcare system this year where they are adopting robotics for use in many of the hospitals throughout France to which Ekso is being selected for many of them. Speaker 400:13:18I see, I see. That makes it more clear. Thanks for that. That's all the questions I have. Speaker 200:13:24Thank you, Operator00:13:26Sean. Our next question comes from the line of Ben Haynor with Lake Street. Please proceed with your question. Speaker 500:13:34Good day, gentlemen. Thanks for taking the questions. First off for me, you mentioned the strong demand that you've seen on the Indigo Personal side. Can you maybe share a little bit more color on where that's coming from? Is that directly from the patients? Speaker 500:13:48Is it kind of referrals from neuro rehab providers? And then kind of the process once you do see that you see the demand if it's in this particular case, if it's directly from a patient, how does that kind of work its way through the system and ultimately to get fulfilled by DME? Speaker 300:14:09Okay. Operator00:14:09Thank you. Speaker 200:14:10Thank you, Ben, for the multipart question. So I think we'll get okay. We'll get started with where the leads are coming from. And we're seeing leads both from individuals themselves who are basically coming to our website and inquiring and we are also seeing them through our network of neuro rehab facilities who have spinal cord individuals in their individual spinal cord injuries in their programs. So it's a combination of really the 2 where we're seeing demand. Speaker 200:14:50I would say it's almost evenly matched as we look at the at where those leads are coming from. Now further to your question of what happens and how does the process work from here. Generally speaking, our approach to this is to work with our current customer base. We've got more than 260 centers throughout North America that currently are using Ekso products for neuro rehabilitation. And many of these centers have individuals who have suffered a spinal cord injury in their networks or in their programs. Speaker 200:15:39And we will generally where it makes sense connect that individual with the center for their onboarding and their training. We're also working with DMEs, Durable Medical Equipment Providers, who are processing these claims. So it's not our intent to process individual Medicare claims ourselves, but rather to support our DMEs in getting the information required for that claim and also tying it into a center who can do the onboarding process and training. Speaker 500:16:23Okay, got it. And those and the documentation requirements and such that the DMEs need to fulfill, how much easier is it than the kind of the previous situation? Speaker 200:16:38It's substantially easier now that there is final payment determination set. And I think the level of comfort by physicians who are writing prescriptions for this is at a much higher level, at least from what we've seen. So in general, having final payment determination makes this a substantially more straightforward program. However, as with any new program, we do expect a ramp up over time. So this is not quite as easy as turning on a faucet. Speaker 200:17:21It is a new program for reimbursement. Reimbursing exoskeletons in lump sum as a brace is something that is new. And so we are taking a very deliberate approach to this with our DMEs, with the supporting physicians and with the patients to ensure that we have good and comprehensive claims that are being submitted through CMS. Speaker 500:17:49Okay, got it. And it's kind of the physicians default mindset like I'll write a prescription and make sure this goes all the way through before I write another one or are they comfortable with the reimbursement level being in place to go ahead and write a handful of scripts right out of the gate? Speaker 200:18:09Well, I think that's a difficult question to answer as the early claim submissions that we've been supporting on have been from multiple physicians as opposed to through a single one. So it's I can't really answer that at this point. I would imagine that once a physician has done one successfully, it will become easier. That's my assumption. Speaker 500:18:41Okay. That makes sense. And then on the 2 60 plus centers that you're in, have you seen increased interest on the XLNR side just now that the reimbursement for the personal Speaker 200:18:55devices is available? I certainly think that the continuum of care story that we can now tell with being able to bring a patient from hospital through to home resonates with the centers. We've heard that from many of our centers that they're excited about that. Will that actually result in potentially more NR sales? That's TBD. Speaker 200:19:29We do know that there's been a lot of positive feedback around our Gate Coach software, which has been newly introduced in the North American market that really helps drive ease of use in operating our exoskeleton. So where we do anticipate seeing some growth in centers that are beginning to do more with individuals with spinal cord injuries in their outpatient facilities, some of those centers may elect to look at using our Ekso Indigo therapy, which is really a resizable version of our personal device. So we have seen some additional interest in that particular product category. Speaker 500:20:21Okay, got it. And then lastly for me on the $1,000,000 increase in the backlog. Was that sorry if I missed it, was that worldwide or is that just U. S. Or North America? Speaker 500:20:34And then is France with their rollout a big portion of that or what's the right way to think about that from an international standpoint? Speaker 200:20:45Yes. So great question. Largely the backlog that we have, it represented both North America and EMEA. And I will say that probably a larger portion of that is reflective of the EMEA opportunity, specifically the one with the French healthcare system. Speaker 500:21:10Okay, great. Well, congrats on the progress gentlemen and getting the reimbursement at close. Thank you very much. Speaker 200:21:17We're excited. Thanks a lot, Ben. Appreciate it. Operator00:21:21There are no further questions in the queue. I'd like to hand it back to Scott Davis for closing remarks. Speaker 200:21:28All right. Thank you, Doug, and thank you to everyone joining us today. Overall, the Q1 of 2024 was an encouraging start to the year, particularly following the final pricing determination for the Ekso Indigo Personal. With thousands of individuals with spinal cord injuries that could benefit from our personal device, we believe this is a potentially transformative event for Ekso. In addition to this positive development, we look forward to sustaining our commercial growth, while continuing to work to expand the market for our enterprise health products with new and existing IDNs and for EVO in large industrial settings. Speaker 200:22:03We look forward to providing updates on our continued progress. Thank you and have a great day. Operator00:22:10Ladies and gentlemen, this does conclude today's teleconference. Thank you for your participation. You may disconnect your lines at this time and have a wonderful day.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallProvident Bancorp Q1 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsSlide DeckPress Release(8-K)Quarterly report(10-Q) Provident Bancorp Earnings HeadlinesWith 40% ownership, Provident Bancorp, Inc. (NASDAQ:PVBC) has piqued the interest of institutional investorsFebruary 21, 2025 | finance.yahoo.comProvident Bancorp Full Year 2024 Earnings: EPS Beats ExpectationsJanuary 25, 2025 | finance.yahoo.comTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionApril 20, 2025 | Crypto 101 Media (Ad)Provident Bancorp Inc (PVBC) Shares Up 5.17% on Jan 24January 24, 2025 | gurufocus.comProvident Bancorp Inc Q4 2024 Earnings: EPS of $0.29 Beats Estimates, Revenue at $13. ...January 23, 2025 | gurufocus.comProvident Bancorp, Inc. Reports Fourth Quarter Net Income of $4.9 MillionJanuary 23, 2025 | prnewswire.comSee More Provident Bancorp Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Provident Bancorp? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Provident Bancorp and other key companies, straight to your email. Email Address About Provident BancorpProvident Bancorp (NASDAQ:PVBC), Inc. is a Maryland corporation that was formed in 2019 to be the successor corporation to Provident Bancorp, Inc., a Massachusetts corporation, and the holding company for The Provident Bank. The Provident Bank, a subsidiary of Provident Bancorp, Inc. is an innovative, commercial bank that finds solutions for its business and private clients.View Provident Bancorp ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:00Greetings and welcome to the Ekso Bionics First Quarter 20 24 Financial Results Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce Matt Steinberg with Fin Partners. Operator00:00:26Thank you. You may begin. Speaker 100:00:28Thank you, operator, and thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer Jerome Wong, Chief Financial Officer and Jason Jones, Chief Operating Officer. Earlier today, Ekso Bionics released financial results for the quarter ended March 31, 2024. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Speaker 100:01:11Any statements made during this call that are not statements of historical facts should be deemed to be forward looking statements. All forward looking statements, including statements regarding our business strategy, future financial or operational expectations or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with Ekso's businesses, please see its filings with the Securities and Exchange Commission. Speaker 100:02:00Ekso disclaims any obligation, except as required by law, to update or revise any financial or operational projections, its regulatory outlook or other forward looking statements, whether because of new information, future events or otherwise. Any forward looking statements made on this call speak only as of the date of this call. I will now turn the call over to Ekso Bionics' Chief Executive Officer, Scott Davis. Speaker 200:02:28Thank you, Matt. We closed out the Q1 and started the Q2 of 2024 with positive momentum as we were pleased to receive final payment determination for Medicare reimbursement of our Ekso Indigo Personal. Additionally, our results for the quarter reflect continued improvements from both our scalable commercial strategy and operations. I'll touch on both of these developments shortly, but first I'll share an overview of our Q1 performance. We generated revenue of $3,800,000 and sold 29 EksoHealth devices in the Q1 of 2024. Speaker 200:03:04Sales of the EksoHealth devices for the quarter were slightly more affected by typical seasonality due primarily to fluctuations in larger integrated delivery network or IDM procurement cycles. We remain focused on executing upon our commercial strategy and growing our IDN network. We continue to deploy resources to develop new IDN relationships that will help us secure larger and more multi unit capital deals across our North American network. In doing so, we aim to convey the clear clinical and economic benefits of our EksoNR and our Ekso Indigo Therapy devices with the right decision makers. Our pipeline of potential deals remains solid with approximately $1,000,000 of backlog generated in Q1 to be recognized over the course of 2024 and we remain confident that our commercial team will succeed in driving larger unit order growth. Speaker 200:04:01Now turning to an Ekso Indigo personal update. As previously announced, CMS approved use of healthcare common procedure coding system K1007 to bill Medicare for the Ekso Indigo Personal. On April 11, CMS established a reimbursement level of $91,031 for Medicare reimbursement under this code, the Ekso Indigo Personal, effective retroactively beginning April 1. This pricing decision from CMS is an important next step in our commercial strategy to build demand within clinical, home and community use settings. We believe there are thousands of Medicare and Medicaid covered individuals with a spinal cord injury that could potentially benefit from our differentiated personal exoskeleton device, enabling them to achieve better health outcomes along with new levels of independence. Speaker 200:04:56We're thrilled that our differentiated exoskeleton devices are now accessible to a larger patient population and we look forward to providing future updates on our continued work with the SCI community, CMS, along with other public and private health insurance programs that generally follow CMS reimbursement practices. With reimbursement pricing secured, we anticipate growing the personal health business. We believe this growth will ramp up quarter over quarter as our commercial and clinical teams engage with skilled therapists and clinicians across our expansive customer base consisting of more than 260 clinical and rehabilitation centers domestically. We're leveraging our robust network to expand our reach to a potentially higher volume of individuals living with a spinal cord injury who we benefit from our Ekso Indigo Personal through establishing additional certified training centers across the U. S. Speaker 200:05:49Turning to our international performance, we're pleased that we continue to gain momentum across the EMEA and APAC regions. Results were particularly strong in EMEA as the French public health system has embraced the use of robotics in their neuro rehabilitation programs. Looking ahead, we are working to continue to build on the strength of our vast international distribution network, which serves as our focal point of achieving operating leverage and scalable worldwide growth. Now I'd like to turn to an update on our Industrial segment, EksoWorks. In the Q1 of 2024, sales within this segment increased nearly 60% from the same period a year ago, although against a modest level. Speaker 200:06:31Notably, we delivered devices to an OEM in the construction vertical along with continued shipments to potentially large volume customers in aerospace and energy segments. With improved cost structures driven by our new contract manufacturer, we remain focused on scaling our commercial growth through targeted customers in large industrial settings. Overall, our performance in the Q1 of 2024 demonstrated continued progress across both of our segments. Now with CMS establishing reimbursement pricing for the Ekso Indigo Personal, we believe we are poised to take the next step in our evolution. At this time, I'd like to turn the call over to our Chief Financial Officer, Jerome Wong to review our Q1 financial results. Speaker 300:07:15Thank you, Scott. We generated Q1 2024 revenue of $3,800,000 compared to $4,100,000 for the Q1 of 20 23. Gross profit for the 1st quarters of 20242023 was CAD2 1,000,000 in both periods, representing a gross margin of approximately 52% in the Q1 of 2024 compared to a gross margin of 49% for the Q1 of 2023. The overall increase in gross margin was primarily due to lower EksoHealth device and service costs. Operating expenses for the Q1 of 2024 were $5,200,000 compared to $6,400,000 for the Q1 of 2023. Speaker 300:08:00The 19% decrease was primarily due to a decrease in general and administrative expenses stemming from lower legal expenses, headcount and the absence of costs associated with the acquisition and integration of HMC in the comparable quarter. Net loss applicable to common stockholders for the Q1 was $3,400,000 or $0.20 per basic and diluted share, compared to a net loss of $4,400,000 or $0.33 per basic and diluted share for the same period in 2023. Cash and restricted cash as of March 31, 2024 was $8,800,000 compared to $8,600,000 as of December 31, 2023. Please see our Form 10 Q filed earlier today for further details regarding the quarter. Operator, you may now open the line for questions. Operator00:08:55Thank you. Ladies and gentlemen, at this time, we will be conducting a question and answer Our first question comes from the line of Sean Lee with H. C. Wainwright. Please proceed with your question. Speaker 400:09:31Good afternoon, guys. This is Sean from H. C. Wainwright. How are you? Speaker 200:09:37I'm well, Sean. Thank you. Speaker 400:09:40My first question is on the recent approval by Medicare on the reimbursement. So I was wondering, it's been about 2 weeks since, have you seen any increase in lead generation or interest in this device as a result of the Medicare approval? Speaker 200:09:59Yes. So thank you, Shlomo, for your question. In general, we are seeing strong demand from individuals with spinal cord injuries who are interested in the technology. So we saw a definite uptick from the announcement of final payment termination. So yes, is the short answer to that question. Speaker 200:10:28And we are working to support our DMEs to be able to get those Medicare claims submitted. Speaker 400:10:40That's great to hear. On the elaborating on these claims, so I was wondering, does having a standardized reimbursement number streamline your sales cycle such that it makes it easier for you to market and sell these devices? Speaker 200:11:02Again, the short answer to that is yes, absolutely. Previously, with the code approved, but on a case by case basis, the level of documentation that's required for that is fairly significant. And it's a rather unusual process to physicians who might be submitting a prescription for this or to DMEs who need to process it. With CMS establishing a payment determination, this claim now has an actual cash value behind it. So as those claims are being submitted, there is a recognized value that has been definitively provided by CMS. Speaker 200:11:56So it is a more of a standardized process at this point in time. Speaker 400:12:02That's great to hear. Thanks for that. My final question then is on the international sector. You mentioned that you're gaining momentum, especially in India. So I was wondering, is that something that we could see going forward for the remainder of the year as well? Speaker 400:12:17Or is it more of a one time bolus in the Q1? Speaker 200:12:22Okay. In the EMEA region, yes. So we are seeing good growth there and part of that growth is attributed to the strong distribution network that we've built throughout both EMEA and APAC regions. We've been hard at work in developing our distributor network over many years now and we are definitely seeing scale through that use of that channel. Additionally, there's been a significant project within the French healthcare system this year where they are adopting robotics for use in many of the hospitals throughout France to which Ekso is being selected for many of them. Speaker 400:13:18I see, I see. That makes it more clear. Thanks for that. That's all the questions I have. Speaker 200:13:24Thank you, Operator00:13:26Sean. Our next question comes from the line of Ben Haynor with Lake Street. Please proceed with your question. Speaker 500:13:34Good day, gentlemen. Thanks for taking the questions. First off for me, you mentioned the strong demand that you've seen on the Indigo Personal side. Can you maybe share a little bit more color on where that's coming from? Is that directly from the patients? Speaker 500:13:48Is it kind of referrals from neuro rehab providers? And then kind of the process once you do see that you see the demand if it's in this particular case, if it's directly from a patient, how does that kind of work its way through the system and ultimately to get fulfilled by DME? Speaker 300:14:09Okay. Operator00:14:09Thank you. Speaker 200:14:10Thank you, Ben, for the multipart question. So I think we'll get okay. We'll get started with where the leads are coming from. And we're seeing leads both from individuals themselves who are basically coming to our website and inquiring and we are also seeing them through our network of neuro rehab facilities who have spinal cord individuals in their individual spinal cord injuries in their programs. So it's a combination of really the 2 where we're seeing demand. Speaker 200:14:50I would say it's almost evenly matched as we look at the at where those leads are coming from. Now further to your question of what happens and how does the process work from here. Generally speaking, our approach to this is to work with our current customer base. We've got more than 260 centers throughout North America that currently are using Ekso products for neuro rehabilitation. And many of these centers have individuals who have suffered a spinal cord injury in their networks or in their programs. Speaker 200:15:39And we will generally where it makes sense connect that individual with the center for their onboarding and their training. We're also working with DMEs, Durable Medical Equipment Providers, who are processing these claims. So it's not our intent to process individual Medicare claims ourselves, but rather to support our DMEs in getting the information required for that claim and also tying it into a center who can do the onboarding process and training. Speaker 500:16:23Okay, got it. And those and the documentation requirements and such that the DMEs need to fulfill, how much easier is it than the kind of the previous situation? Speaker 200:16:38It's substantially easier now that there is final payment determination set. And I think the level of comfort by physicians who are writing prescriptions for this is at a much higher level, at least from what we've seen. So in general, having final payment determination makes this a substantially more straightforward program. However, as with any new program, we do expect a ramp up over time. So this is not quite as easy as turning on a faucet. Speaker 200:17:21It is a new program for reimbursement. Reimbursing exoskeletons in lump sum as a brace is something that is new. And so we are taking a very deliberate approach to this with our DMEs, with the supporting physicians and with the patients to ensure that we have good and comprehensive claims that are being submitted through CMS. Speaker 500:17:49Okay, got it. And it's kind of the physicians default mindset like I'll write a prescription and make sure this goes all the way through before I write another one or are they comfortable with the reimbursement level being in place to go ahead and write a handful of scripts right out of the gate? Speaker 200:18:09Well, I think that's a difficult question to answer as the early claim submissions that we've been supporting on have been from multiple physicians as opposed to through a single one. So it's I can't really answer that at this point. I would imagine that once a physician has done one successfully, it will become easier. That's my assumption. Speaker 500:18:41Okay. That makes sense. And then on the 2 60 plus centers that you're in, have you seen increased interest on the XLNR side just now that the reimbursement for the personal Speaker 200:18:55devices is available? I certainly think that the continuum of care story that we can now tell with being able to bring a patient from hospital through to home resonates with the centers. We've heard that from many of our centers that they're excited about that. Will that actually result in potentially more NR sales? That's TBD. Speaker 200:19:29We do know that there's been a lot of positive feedback around our Gate Coach software, which has been newly introduced in the North American market that really helps drive ease of use in operating our exoskeleton. So where we do anticipate seeing some growth in centers that are beginning to do more with individuals with spinal cord injuries in their outpatient facilities, some of those centers may elect to look at using our Ekso Indigo therapy, which is really a resizable version of our personal device. So we have seen some additional interest in that particular product category. Speaker 500:20:21Okay, got it. And then lastly for me on the $1,000,000 increase in the backlog. Was that sorry if I missed it, was that worldwide or is that just U. S. Or North America? Speaker 500:20:34And then is France with their rollout a big portion of that or what's the right way to think about that from an international standpoint? Speaker 200:20:45Yes. So great question. Largely the backlog that we have, it represented both North America and EMEA. And I will say that probably a larger portion of that is reflective of the EMEA opportunity, specifically the one with the French healthcare system. Speaker 500:21:10Okay, great. Well, congrats on the progress gentlemen and getting the reimbursement at close. Thank you very much. Speaker 200:21:17We're excited. Thanks a lot, Ben. Appreciate it. Operator00:21:21There are no further questions in the queue. I'd like to hand it back to Scott Davis for closing remarks. Speaker 200:21:28All right. Thank you, Doug, and thank you to everyone joining us today. Overall, the Q1 of 2024 was an encouraging start to the year, particularly following the final pricing determination for the Ekso Indigo Personal. With thousands of individuals with spinal cord injuries that could benefit from our personal device, we believe this is a potentially transformative event for Ekso. In addition to this positive development, we look forward to sustaining our commercial growth, while continuing to work to expand the market for our enterprise health products with new and existing IDNs and for EVO in large industrial settings. Speaker 200:22:03We look forward to providing updates on our continued progress. Thank you and have a great day. Operator00:22:10Ladies and gentlemen, this does conclude today's teleconference. Thank you for your participation. You may disconnect your lines at this time and have a wonderful day.Read morePowered by